Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    17-July-2000      
Issue 95 Next Update - 14:00 UTC 08:00 EST    18-July-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya Drug Company Says UNAIDS Condemnation of Nonoxynol-9 Results From a Faulty Study

Study's Conclusions Are Premature; Study Itself Riddled With Ethical Errors

Columbia Laboratories commented in response to a press release issued by UNAIDS that Nonoxynol-9 may raise the rate of HIV infection rather than lower it.

In the study, it was reported that Advantage-S is a sustained and controlled release formulation containing 52.5 MG of N9 per dose initially designed to be used once daily. WHO/UNAIDS conducted and published a study demonstrating it was safe to use at that dose (AIDS 1998, 12:433-437). This was misleading. Subsequently, a safety trial was conducted by UNAIDS administering the product four times per day in female sex workers and it again was judged to be safe.

In the UNAIDS Phase III clinical trial no upper limit was put on dosing. In fact, the protocol encouraged women to use the product after each act of intercourse, which ranged from 0-20 per day. Women who used the product per-protocol may have used 10 or even 20 doses in a day. At this dose, previous studies have shown that N9 causes local lesions and is probably unsuitable as a microbicide. Advantage-S was designed to avoid this problem and by not limiting the dose to that which was tested and shown to be safe, the study encouraged women to dose themselves to a toxic level.

"Before UNAIDS condemns N9 per se or Advantage-S, careful analysis of the data should be conducted to see if there is a correlation between the dose administered and the increased risk of transmission of HIV," commented William J. Bologna, Chairman and CEO of Columbia Laboratories, Inc.

"The maximum tolerated dose that was studied in this population was four times per day. Under no circumstances should this dose have been exceeded. Despite this the investigators allowed and even encouraged women to dose themselves to known toxic levels. The most disturbing aspect of this study is that the statistical design was two tailed. This means that it was anticipated from previous studies that a toxic dose of N9 could be reached and thus, when a difference was seen in the interim analysis, the Drug Safety Monitoring Board (DSMB) was obliged to ensure that it was the active group and not the placebo that had a lower incidence of transmission. Their failure to do so is unpardonable and unethical. UNAIDS and the DSMB they appointed may have been grossly negligent in the manner in which they designed and monitored this study."

Columbia Laboratories, Inc. today for the appointment of a team of outside experts to be given unfettered access to all the data from this study and to report their independent findings to the public at large. It is the Company's belief that this is the only manner in which the women who are the victims of this epidemic can be appropriately served.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.